ReviewFrontiers in medicine2017
Historical Evolution of Second-Line Therapy in Non-Small Cell Lung Cancer.
Review in Frontiers in medicine, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed.
- Real-World Effectiveness of Second-Line Therapies in Advanced Non-Small Cell Lung Cancer: Insights From Propensity-Weighted Comparative Analyses of Longitudinal EHR Data.Clinical lung cancer · 2026Article
- Circulating Tumor DNA and [Diagnostics (Basel, Switzerland) · 2025Article
- Blood biomarkers to predict the efficacy of neoadjuvant chemo-immunotherapy in non-small cell lung cancer patients.Translational lung cancer research · 2024Article
- Effectiveness of standard treatments in non-small-cell lung cancer with METexon14 skipping mutation: a real-world study.Future oncology (London, England) · 2024Article
- What Zebrafish and Nanotechnology Can Offer for Cancer Treatments in the Age of Personalized Medicine.Cancers · 2022Review
- Independent Drug Action in Combination Therapy: Implications for Precision Oncology.Cancer discovery · 2022Review
- Functional assessment of somatic STK11 variants identified in primary human non-small cell lung cancers.Carcinogenesis · 2021Article
- MUC3A promotes non-small cell lung cancer progression via activating the NFκB pathway and attenuates radiosensitivity.International journal of biological sciences · 2021Article
- Five-year follow-up results from phase II studies of nivolumab in Japanese patients with previously treated advanced non-small cell lung cancer: pooled analysis of the ONO-4538-05 and ONO-4538-06 studies.Japanese journal of clinical oncology · 2021Article
- Pembrolizumab plus platinum-based chemotherapy for unfavorable cancer of unknown primary site: Case report.Annals of medicine and surgery (2012) · 2020Article
- ACOT11 promotes cell proliferation, migration and invasion in lung adenocarcinoma.Translational lung cancer research · 2020Article
- Immunotherapies and Combination Strategies for Immuno-Oncology.International journal of molecular sciences · 2020Review
- The Crosstalk between Src and Hippo/YAP Signaling Pathways in Non-Small Cell Lung Cancer (NSCLC).Cancers · 2020Review
- Prior acquired resistance to paclitaxel relays diverse EGFR-targeted therapy persistence mechanisms.Science advances · 2020Article
- Nitidine chloride possesses anticancer property in lung cancer cells through activating Hippo signaling pathway.Cell death discovery · 2020Article
- Trial watch: chemotherapy-induced immunogenic cell death in immuno-oncology.Oncoimmunology · 2020Review
- Combined Checkpoint Inhibition and Chemotherapy: New Era of 1Molecular therapy oncolytics · 2019Review
- Pharmacokinetic Profile of Inhaled Submicron Particle Paclitaxel (NanoPacJournal of aerosol medicine and pulmonary drug delivery · 2019Article
- Immune-Checkpoint Inhibitors as the First Line Treatment of Advanced Non-Small Cell Lung Cancer: A Meta-Analysis of Randomized Controlled Trials.Journal of Cancer · 2019Review
- Tumor targeting with docosahexaenoic acid-conjugated docetaxel for inhibiting lung cancer metastasis to bone.Oncology letters · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Innovative therapeutic agents have significantly improved outcome with an acceptable safety profile in a substantial proportion of non-small cell lung cancer (NSCLC) patients, who depend on oncogenic molecular alterations for their malignant phenotype. Despite the survival improvement achieved with first-line chemotherapy, about 30% of patients do not obtain a tumor response. Moreover, those patients, initially sensitive to treatment, acquire resistance and develop tumor progression after a median of about 5 months. Approximately 60% of the patients progressing from first-line chemotherapy receive further systemic treatment in the second-line setting. Moreover, new options have emerged in the second-line armamentarium for the treatment of patients with NSCLC, including immune checkpoint inhibitors and antiangiogenic agents. The current review provides an overview on the clinical studies that gained the approval of chemotherapy agents (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.